Agentic artificial intelligence could fundamentally reshape how pharmaceutical companies engage healthcare professionals within the next two years, according to a new industry report released this week by Doceree.

The report, Doceree 360: Understanding HCP Engagement in the Age of AI (2025 Edition), forecasts a shift away from campaign-based marketing toward AI-driven, workflow-embedded engagement—where intelligence is delivered directly within clinical environments rather than through scheduled promotional touchpoints.

By 2026–27, Doceree projects that agentic AI systems will enable credible, context-aware scientific exchange at scale, supporting clinicians with validated information while operating within strict regulatory and compliance guardrails. Industry modeling cited in the report suggests productivity gains of 30 to 45 percent, alongside automation of up to 75 to 85 percent of existing pharma–HCP workflows over the next five years.

Rather than replacing human representatives, the report argues, AI agents will increasingly handle high-volume, repetitive interactions—such as query resolution and continuity of engagement—allowing field teams to focus on complex, relationship-driven work.

“We are entering a phase where AI doesn’t just support engagement—it defines it,” said Harshit Jain, founder and global chief executive of Doceree. Clinicians, he said, operate under intense time pressure and cognitive load, creating demand for tools that deliver approved information instantly, consistently, and without scheduling friction.

Also Read: GenAI Search Is Rewriting the Shopper’s Playbook

Six shifts shaping the next phase of pharma marketing

The report outlines six developments it expects to define pharmaceutical marketing over the next two years:

Agentic AI as the primary interface.

By 2027, AI systems capable of reasoning within clinical, regulatory, and brand constraints are expected to become the default engagement layer, with human representatives focusing on nuanced, high-stakes interactions.

Clinical workflows as the new frontier in engagement.

Engagement is forecast to move deeper into point-of-care systems, with real-time decision intelligence delivered inside electronic health records only when clinically relevant.

Unified platforms replacing fragmented tools.

Pharma organizations are expected to consolidate dozens of disconnected systems into single orchestration layers governing content, compliance, identity resolution, measurement, and AI decisioning.

Affordability intelligence is becoming essential.

With patient cost increasingly influencing prescribing behavior, the report points to embedded co-pay and access intelligence as a critical differentiator in clinician engagement.

Personalization shifting to live context.

Rather than relying on static segments, AI systems will adapt engagement in real time based on what a clinician is doing at a given moment.

Creative quality is becoming measurable.

As targeting and timing are optimized by AI, creative effectiveness—visual hierarchy, messaging clarity, compliance adherence, and emotional resonance—will become a quantifiable lever of performance.

Also Read: Edition 3: Sharp Minds Decoding Tech’s Next Wave

Kamya Elawadhi, Doceree’s Chief Client Officer, said the transition will depend on establishing trust. “Brands that govern agentic AI properly—training it on verified sources and ensuring clinical credibility—can move from being information providers to trusted partners in care,” she said.

The report stops short of predicting uniform adoption, noting that regulatory oversight, data governance, and organizational readiness will determine how quickly agentic systems are deployed. Still, its conclusion is clear: as AI becomes embedded in clinical workflows, the economics and ethics of pharma–HCP engagement are poised for a structural reset.

The post Agentic AI May Redraw Pharma–Doctor Engagement appeared first on MartechView.